ClinicalTrials.gg
CompletedNCT03962998Updated Jun 10, 2022

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

An Early Phase 1 interventional study of Lactulose/Rhamnose solution and MB-102 in Crohn Disease, sponsored by MediBeacon. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-06-10.

Sponsored by MediBeacon · Early Phase 1, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was Oct 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
380th of 528
22 · median 60
Started
2019
with 34 others
Phase 1
58 of 660
5 open now
Registered
424th of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 380th largest by enrollment of the 528 interventional ones that give a count, is one of 35 that started in 2019, is one of 58 in phase 1, and was the 424th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

The objectives of the study are to evaluate the safety and tolerability of oral administration of MB-102, and to evaluate the use of MB-102 as a means of measuring gut permeability in normal participants (n=10) and in those with radiologic evidence of small bowel Crohn's disease (n=10).

Read the detailed description

This study is a single center, randomized, open label, cross-over study evaluating MB-102 versus dual sugar testing using lactulose and rhamnose for the assessment of gut permeability. Participants will be screened within 30 days of Day 1, and eligible participants will be randomized to receive either an oral dose of MB-102 or the dual sugar test on Day 1. At a second study visit occurring between 3 to 7 days after completion of the first test, participants will return to the study center for the second test. Following completion of the second test, participants will return to the study center 7 ±3 days for a follow-up visit to evaluate safety.

03

Conditions studied

  • Crohn Disease

Browse trials for

Keywords

  • Gut permeability
  • Intestinal permeability
  • MB-102
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years - male or non-pregnant or lactating females
  • Participants willing to comply with study requirements
  • Participants who have signed an form
  • Normal or non- screening and baseline 12 lead (ECG) in the opinion of the principal investigator (PI)
  • Estimated glomerulofiltration rate () > 75 mL/min/1.73 m\^2
  • Agreement to not utilize nonsteroidal anti-inflammatory drugs (NSAIDs) until study completion.

Inclusion criteria for participants with Crohn's disease:

  • Participants with active small bowel Crohn's disease diagnosed by an abnormal Magnetic Resonance Enterography (MRE) within 1 month prior to screening
  • Active Crohn's disease must be characterized by mucosal hyperemia, and/or bowel wall thickening and/or vascular engorgement

Exclusion criteria

Exclusion criteria for all participants:

  • Women who are pregnant, lactating, or planning to become pregnant during the study, or women who are of unwilling to use an adequate method of a. Males must be willing to practice abstinence or utilize adequate contraception from dosing day to at least 7 days post dose
  • Participation in another interventional trial within 30 days of dosing or concurrently enrolled in any other medical research study which could impact the results of the study
  • Unable to tolerate an overnight fast
  • NSAID use within 14 days of Day 1
  • History of drug or alcohol abuse within the past year
  • Diagnosis of ulcerative colitis, indeterminate colitis, pseudomembranous colitis, or celiac disease
  • Prior or current diagnosis of an disease
  • Gastrointestinal surgery (including appendectomy) within 12 weeks prior to screening or has surgery planned or deemed likely to require surgery during the study
  • Type 1 or 2 diabetes
  • History of severe allergic reactions (unacceptable adverse events) or anaphylactoid reaction to any allergen including drugs, or MB-102 (intolerance to a drug is not considered a drug allergy)
  • Known history of testing positive for acquired immunodeficiency syndrome (AIDS) or (HIV)
  • Site personnel immediately associated with the study or their immediate family members
  • Any characteristics which, in the opinion of the investigator, makes the participant a poor candidate for participation in the clinical trial
  • Prior exposure to MB-102
  • Any changes to chronic medication therapy or initiation of new medications between Testing Day 1 and Testing Day 2
  • Current urinary tract infection
  • > 30 kg/m\^2
  • Prior history of small bowel or resection surgery
  • Unable to meet the requirements of the study including 12+ hour study visits

Additional exclusion criteria for normal participants:

  • Fecal transplant within 1 year
  • Prior or current graft-vs.-host disease
  • Prior or current history of diverticulitis
  • Current or prior history of fatty liver
  • Current use of any biologic therapy or current use of the following medications: sulfasalazine, mesalamine, olsalazine, balsalazide, prednisone, cyclosporine, azathioprine, 6-mercaptopurine, tacrolimus, methotrexate, intravenous immunoglobulin, anti-diarrheal agents
  • Prior antibiotic therapy within 30 days of screening
  • Undiagnosed chronic gastrointestinal upset or food intolerance history
  • Recent history of significant unplanned weight loss, blood in the stool or acute episodes of diarrhea
  • First-degree relative (sibling, parent, child) has inflammatory bowel disease (Crohn's disease, ulcerative colitis, proctitis, indeterminate colitis)
  • History of Crohn's disease

Additional exclusion criterion for participants with Crohn's disease:

  • Participant on Total Parenteral Nutrition (TPN)
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Early Phase 1
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Active comparator
    Lactulose/Rhamnose

    1000 mg of lactulose and 200 mg of rhamnose administered orally as a 10 mL solution

    Drug: Lactulose/Rhamnose solution

  • Experimental
    MB-102

    4 μmol of MB-102/kg body weight administered orally as a solution

    Drug: MB-102

Interventions

  • DrugLactulose/Rhamnose solution

    Drug page: Lactulose

    Lactulose/Rhamnose solution administered orally followed by measurement of excreted lactulose and rhamnose in urine

  • DrugMB-102

    MB-102 solution administered orally followed by measurement of excreted MB-102 in urine

06

What researchers measure

Primary outcomes

  1. Mean urine concentration of MB-102 over time in normal participants and in those with Crohn's disease

    Urine samples will be collected pre-dose (time 0), each time the participant voids, and at the protocol-defined time points after oral administration of MB-102. The total volume of urine excreted will be recorded. Urine samples will be analyzed using validated analytical methods.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 10, and 12 hours

Secondary outcomes

  1. Correlation between MB-102 excretion and the results of dual sugar testing in normal participants and in those with Crohn's disease

    For MB-102 excretion evaluation, urine samples will be collected pre-dose (time 0), each time the participant voids, and at the protocol-defined time points after oral administration of MB-102. The total volume of urine excreted will be recorded. Urine samples will be analyzed using validated analytical methods. For the dual sugar test, participants will consume a 10 mL solution (1000 mg of lactulose and 200 mg of rhamnose). Urine will be collected pre-dose (time 0), each time the participant voids, and at the protocol-defined time points after consuming the sugar solution. The total volume of urine excreted will be recorded. Urine samples will be analyzed using validated analytical methods.

    Time frame: Pre-dose and 1, 2, 4, 6, 8, 10, and 12 hours

07

Study locations

1 site
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Oct 2021, 23 months.

Of 33 industry-sponsored phase 1 interventional studies under Crohn Disease, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 23 months is above that.

Counting every sponsor, half of 61 studies reached it within 22 months; a quarter within 10 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2019
First posted
May 24, 2019
StartActual
Oct 27, 2019
Primary completionActual
Oct 5, 2021
CompletionActual
Oct 5, 2021
Last update
Jun 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03962998
Lead sponsor
MediBeacon
Responsible party
Sponsor
First posted
May 24, 2019
Start date
Oct 27, 2019
Primary completion
Oct 5, 2021
Completion
Oct 5, 2021
Last update
Jun 10, 2022

Study contacts

Richard B Dorshow, PhD
study director · MediBeacon

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Relmapirazin

Start the discussion